Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Free Report) have been given a consensus recommendation of “Hold” by the nine analysts that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.24.

A number of equities research analysts have recently commented on the company. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. UBS Group lowered their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. HC Wainwright lowered their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th.

Get Our Latest Stock Analysis on Zentalis Pharmaceuticals

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Integral Health Asset Management LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $3,182,000. Verition Fund Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Almitas Capital LLC grew its holdings in shares of Zentalis Pharmaceuticals by 69.3% during the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock worth $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Boxer Capital Management LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $1,364,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock worth $2,605,000 after purchasing an additional 370,511 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $1.77 on Friday. The stock has a market capitalization of $126.14 million, a price-to-earnings ratio of -0.71 and a beta of 1.75. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27. The business’s fifty day moving average is $2.21 and its 200-day moving average is $2.95.

Zentalis Pharmaceuticals Company Profile

(Get Free Report

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.